Emma Wong Fong Sang’s Post

View profile for Emma Wong Fong Sang, graphic

Manager Business Development - Patent Attorney

All investors in the panel “Biotech Funding: Navigating Challenges, Exploring Solutions” at #KnowledgeforGrowth today agreed that the craziness on the biotech capital market might be over, but that this is actual a good thing because the focus is again on substance, on matter not on hype. Christina Takke, Katrien Swerts, Jan Van den Bossche, Richard Reschen, Servaas Michielssens, PhD, CFA were the panelists and Bram Van Parys was the moderator of this session. Companies with good data will get good funding, according to the investors. And if a company can reach milestones without spending too much money, even better. This shows that the company is well organized and can manage its projects well. In Europe companies need to work on shoestring budgets more often, compared to the US, but they are also usually better at it. This is a good thing because most investors want efficient use of cash according to the speakers. And pressure on the budget often also results in smart, creative solutions. The next big think the panelists are keeping a close eye on are the technical fields of obesity, metabolism, siRNA’s, especially in neurobiology in the field of Alzheimer’s and ALS. Further, new biomarkers allow more effective clinical testing, which already resulted for example in the recent amyloid approvals. Precision fermentation, cell free fermentation with increased carbon utilization as an advantage, and capturing CO2, and growing bacteria on CO2 only are also promising fields, as are therapies in oncology brought to other fields such as immunology, as well as AI in health tech and drug development, which is expected to increase speed, reduce costs, and result in better products.

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics